Core Viewpoint - Apimeds Pharmaceuticals US, Inc. has successfully completed its initial public offering, raising $13.5 million to fund clinical trials and other operational needs [1][3]. Group 1: Initial Public Offering Details - The company closed its initial public offering of 3,375,000 shares at a price of $4.00 per share, with trading commencing on May 9, 2025 [1]. - Gross proceeds from the offering amounted to $13.5 million before expenses [1]. - Underwriters were granted a 45-day option to purchase an additional 506,250 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to fund a Phase III clinical trial for knee osteoarthritis [3]. - The company plans to initiate at least one non-registered corporate sponsorship study in multiple sclerosis [3]. - Proceeds will also be allocated for manufacturing its product candidate and general working capital needs [3]. Group 3: Company Overview - Apimeds is a clinical stage biopharmaceutical company developing Apitox, a bee venom-based toxin with potential therapeutic effects [6]. - The product is being developed as a treatment for knee pain in osteoarthritis patients who do not respond adequately to conventional therapies [6].

Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the pricing of its initial public offering of 3,375,000 shares of common stock at a price of $4.00 per share. The gross proceeds to Apimeds from the offering, b ...